Dino Rossi - Balchem Executive Chairman

BCPC Stock  USD 154.95  0.49  0.32%   

Chairman

Mr. Dino A. Rossi is no longer NonExecutive Chairman of the Board of the Company. Mr. Rossi was President and Chief Executive Officer of the Company since October 1997 Chief Financial Officer of the Company from April 1996 to January 2004 and Treasurer of the Company from June 1996 to June 2003. He was Vice President Finance and Administration of Norit Americas Inc. a whollyowned subsidiary of Norit N.V. a Dutch chemicals company from January 1994 to February 1996 and Vice President Finance and Administration of Oakite Products Inc. a specialty chemicals company from 1987 to 1993. Mr. Rossi served as a director of Scientific Learning Corporation from February 2010 to August 2012. Mr. Rossis years of experience as the primary source of corporate and operational leadership for the Company and his experience with other manufacturing entities make him a valuable member of our Board of Directors. since 2015.
Age 60
Tenure 9 years
Address 5 Paragon Drive, Montvale, NJ, United States, 07645
Phone845 326 5600
Webhttps://www.balchem.com
Rossi was President and Chief Executive Officer of the Company since October 1997, Chief Financial Officer of the Company from April 1996 to January 2004 and Treasurer of the Company from June 1996 to June 2003. He was Vice President, Finance and Administration of Norit Americas Inc., a whollyowned subsidiary of Norit N.V., a Dutch chemicals company, from January 1994 to February 1996, and Vice President, Finance and Administration of Oakite Products Inc., a specialty chemicals company, from 1987 to 1993. During the last five years, Mr. Rossi served as a director of Scientific Learning Corporationration .

Balchem Management Efficiency

The company has return on total asset (ROA) of 0.0609 % which means that it generated a profit of $0.0609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.109 %, meaning that it created $0.109 on every $100 dollars invested by stockholders. Balchem's management efficiency ratios could be used to measure how well Balchem manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.21. The current year's Return On Assets is expected to grow to 0.11. At present, Balchem's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 15.7 M, whereas Net Tangible Assets are forecasted to decline to about 129 M.
The company currently holds 330.33 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Balchem has a current ratio of 2.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Balchem until it has trouble settling it off, either with new capital or with free cash flow. So, Balchem's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Balchem sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Balchem to invest in growth at high rates of return. When we think about Balchem's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 3 records

CHAIRMAN Age

Richard NigonNorthern Technologies
70
John SchmitzSelect Energy Services
64
Neal SchmaleWD 40 Company
71
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York. Balchem Cp operates under Specialty Chemicals classification in the United States and is traded on NASDAQ Exchange. It employs 1382 people. Balchem (BCPC) is traded on NASDAQ Exchange in USA. It is located in 5 Paragon Drive, Montvale, NJ, United States, 07645 and employs 1,302 people. Balchem is listed under Specialty Chemicals category by Fama And French industry classification.

Management Performance

Balchem Leadership Team

Elected by the shareholders, the Balchem's board of directors comprises two types of representatives: Balchem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Balchem. The board's role is to monitor Balchem's management team and ensure that shareholders' interests are well served. Balchem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Balchem's outside directors are responsible for providing unbiased perspectives on the board's policies.
Frederic Boned, Senior Health
Brent Tignor, Senior Officer
Karin McCaffery, IR Contact
Hatsuki Miyata, General VP
Paul Coombs, Independent Director
William CPA, VP Officer
Edward McMillan, Independent Director
Mary Coelho, CFO, Chief Accounting Officer
Carl Bengtsson, CFO Treasurer
Job Gunsteren, Senior Products
Theodore Harris, CEO and President and Director
John Kuehner, Vice President - Operations, Executive Officer
David Fischer, Independent Director
Terry Coelho, CFO, Chief Accounting Officer
Mark Stach, General Counsel, Secretary
Jonathan Griffin, Senior Health
CPA CPA, Chief Officer
Francis Fitzpatrick, Vice President - Administration
John Televantos, Lead Independent Director
Scott Mason, Vice President of Manufacturing and Supply Chain
William Backus, CFO
Suzanne Hart, IR Contact Officer
Martin Bengtsson, CFO
Dino Rossi, Executive Chairman
Daniel Knutson, Director
Michael Sestrick, Senior CTO
David Ludwig, General Manager of ARC Specialty Products and VP
Matthew Wineinger, Director
Mary Brush, IR Contact Officer
Matthew Houston, General Counsel and Secretary
Perry Premdas, Independent Director
Martin Reid, Senior Officer

Balchem Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Balchem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Balchem

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Balchem position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Balchem will appreciate offsetting losses from the drop in the long position's value.

Moving together with Balchem Stock

  0.84DNMR Danimer Scientific Financial Report 8th of May 2024 PairCorr

Moving against Balchem Stock

  0.82NANX Nanophase Technol Report 3rd of April 2024 PairCorr
  0.63CC Chemours Financial Report 25th of April 2024 PairCorr
The ability to find closely correlated positions to Balchem could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Balchem when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Balchem - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Balchem to buy it.
The correlation of Balchem is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Balchem moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Balchem moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Balchem can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Balchem offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Balchem's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Balchem Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Balchem Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Balchem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For information on how to trade Balchem Stock refer to our How to Trade Balchem Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Balchem Stock analysis

When running Balchem's price analysis, check to measure Balchem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Balchem is operating at the current time. Most of Balchem's value examination focuses on studying past and present price action to predict the probability of Balchem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Balchem's price. Additionally, you may evaluate how the addition of Balchem to your portfolios can decrease your overall portfolio volatility.
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Is Balchem's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Balchem. If investors know Balchem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Balchem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.243
Dividend Share
0.79
Earnings Share
3.35
Revenue Per Share
28.729
Quarterly Revenue Growth
(0.02)
The market value of Balchem is measured differently than its book value, which is the value of Balchem that is recorded on the company's balance sheet. Investors also form their own opinion of Balchem's value that differs from its market value or its book value, called intrinsic value, which is Balchem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Balchem's market value can be influenced by many factors that don't directly affect Balchem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Balchem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Balchem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Balchem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.